- Display 15 Products per page
Published: February 1, 2004 | Price: $3,500.00 – $7,000.00
Immunologic approaches to cancer therapy are not only increasing in reputation and number, but the market for these products is increasingly becoming a reality. Vaccines are in the forefront of this approach to cancer, and the handful of cancer vaccine products currently on the market for bladder, colon, and skin cancer are soon to be joined by many more with indications for more wide-spread forms, including lung, breast, ovarian, prostate, leukemia, and others. This new study from Kalorama discusses the...Published: January 1, 2004 | Price: $3,500.00 – $7,000.00
The cost of drug development has soared during the past ten years compelling pharmaceutical and biotechnology companies to look for new, smarter ways of conducting clinical research. Driven by mounting market pressures, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry. This industry has evolved from providing limited clinical trial services...Published: January 1, 2004 | Price: $2,995.00 – $5,990.00
Type II diabetes is a metabolic disease the increases in incidence and prevalence with age. Type II diabetes (also known as "adult onset diabetes" and "non-insulin dependent diabetes") is a disease of glucose metabolism in which the individual becomes resistant to the glucose produced by the pancreas. As a result, glucose is not properly metabolized and serum glucose levels are increased, resulting in numerous complications vascular, renal, neurological and ophthalmological complications as the patient ages. This volume of the Markets...Published: December 1, 2003 | Price: $1,496.00 – $2,992.00
Severe Acute Respiratory Syndrome (SARS), which was a new and unidentified disease when it first affected people, ripped through Asia and Toronto from late 2002 into the summer of 2003, before being contained for the season. Taiwan with just 346 reported cases performed 10,000 diagnostic tests. Three years after West Nile Virus (WNV) first appeared in the United States in 1999 with just 62 cases and 7 deaths, the U.S. Center for Disease Control reports thousands of cases and 150...Published: November 7, 2003 | Price: $746.00 – $1,492.00
Over the past three years, Kalorama Information's analysts have studied drug delivery markets from several angles. In 2001 and 2002, we published a 5-volume series on drug delivery technology, each volume devoted to a route of administration: Volume I: Oral Drug Delivery Volume II: Injectable and Implantable Drug Delivery Volume III: Pulmonary Drug Delivery Volume IV: Transdermal and Transmucousal Drug Delivery Volume V: Advanced Drug Delivery This series segmented the market by technology and included an innovative analysis that estimated...Published: November 1, 2003 | Price: $2,246.00 – $4,492.00
Rheumatoid arthritis is a progressive disease of the joint structure that may be localized or systemic. It varies significantly in severity, producing symptoms that range from minor aches to severe disability and joint deformity. While rheumatoid arthritis can be diagnosed at any age, for childhood to the later years, it most commonly presents with significant symptoms at about middle age. From that point, the disease can progress quickly, slowly or virtually not at all. With an aging population, the unmet...Published: November 1, 2003 | Price: $1,875.00 – $3,750.00
The process of creating a new drug is lengthy and complex. From discovery to development to market, there are numerous pitfalls. In this report, Kalorama focuses on one of the trickiest yet also most promising areas: the interface between discovery and development known as lead optimization. The pressure is on: get better lead compounds faster and at less cost. The amount of money wasted on leads that fail is excessive. And the attrition rate to get a lead is huge....Published: October 1, 2003 | Price: $1,496.00 – $2,992.00
Diagnostic testing for prion diseases has become more important as countries increase the number of tests to battle the potential public health problem. Academic, government, and industry organizations continue to develop diagnostic testing technologies and policies as preventative measures. The number of prion diagnostic technologies being used and developed for prion diseases primarily reflects the scientific and technical challenges of detecting prion proteins. Growth of prion testing will depend on these technology breakthroughs and the future prevalence of prion disease....Published: October 1, 2003 | Price: $2,625.00 – $5,250.00
Growth factors are gene products that play important roles in the regulation of cell division and tissue proliferation. Generally, the binding of a growth factor to its receptor initiates or, in some cases, blocks the ability of cells to divide and multiply. The nature and mode of action of these substances have made them of great interest in various therapeutic areas for which efficacy and specificity must go hand in hand. This report analyzes the world markets for growth factors,...Published: September 1, 2003 | Price: $6,000.00 – $12,000.00
Wound care has come into its own in the last five years and is now recognized as a specialty. The field has become so diverse and dynamic that studying “the wound care market” as a whole is no longer instructive. As technologies begin to be commercialized and products hit the market, segmentation by application is the key to understanding market potential. Kalorama has undertaken a major study to examine each of the three main market segments, in turn: Volume I:...Published: September 1, 2003 | Price: $1,875.00 – $3,750.00
Wound care has come into its own in the last five years and is now recognized as a specialty. The field has become so diverse and dynamic that studying “the wound care market” as a whole is no longer instructive. As technologies begin to be commercialized and products hit the market, segmentation by application is the key to understanding market potential. This Kalorama specialty report will focus on the products that are currently on the market for surgical and trauma...Published: August 1, 2003 | Price: $1,496.00 – $2,992.00
The OTC women’s health market encompasses a wide variety of products that have been determined safe and effective as over-the-counter products. The market is driven by several factors including increasing number of baby boomers entering old age, increasing incidences of diseases; product demand; and several others. In response to many inquiries from readers of Kalorama Information’s March 2003 publication Women’s Health: Worldwide Prescription Drug Markets, 3rd Edition, we embarked on a supplemental study that goes beyond the prescription market to...Published: August 1, 2003 | Price: $2,625.00 – $5,250.00
This Kalorama Information report—Men’s Health: The World Market for Current and Emerging Drug Therapies—focuses on treatment segments in which men are affected. These segments include: · Men’s Cancer · Sexual Function · Sexually Transmitted Diseases · Urinary Conditions · Andropause The report covers drugs that are used for the treatment of conditions affecting men, including prostate cancer, impotence, and BPH; and areas where diseases and men’s health are a major concern including HIV, herpes, and urinary incontinence. Revenues for product...Published: August 1, 2003 | Price: $1,875.00 – $3,750.00
Wound care has come into its own in the last five years and is now recognized as a specialty. The field has become so diverse and dynamic that studying “the wound care market” as a whole is no longer instructive. As technologies begin to be commercialized and products hit the market, segmentation by application is the key to understanding market potential. This Kalorama specialty report will focus on the products that are currently on the market for wound care for...Published: July 18, 2003 | Price: $2,625.00 – $5,250.00
Drug delivery technologies continue to be a vital piece of the pharmaceutical marketing puzzle. From clinical efficacy to product differentiation and life-cycle management, delivery technologies are increasingly demanding the attention of developers at earlier and earlier stages. In Kalorama’s 2001-2002 Drug Delivery series, we focused on the markets by route of administration—oral, injectable, implantable, pulmonary, transdermal etc. In this all new study on advanced drug delivery, however, we focused on drug delivery through the lens of therapeutic application. This report...